What does this research mean for the field?

The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score is a promising biomarker for predicting short-term mortality in cardiovascular disease patients, but has limited predictive value for long-term mortality. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The central aim is to evaluate the prognostic value of the HALP score in predicting long-term mortality in cardiovascular disease patients.

April 13, 2026

EXPRESS: Prognostic Value of the Hemoglobin, Albumin, Lymphocyte, and Platelet Score in Cardiovascular Disease: a systematic review and meta-analysis

Key Points

The central aim is to evaluate the prognostic value of the HALP score in predicting long-term mortality in cardiovascular disease patients.
Conducted a systematic review and meta-analysis of existing literature

Structured PICO

Does the HALP score predict short-term and long-term mortality in patients with cardiovascular disease?

Population

Patients with Cardiovascular Disease (CVD)

Intervention

Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score

Outcome

Short-term mortality (STM) and long-term mortalityhard clinical

The HALP score may serve as a useful prognostic biomarker for short-term mortality in cardiovascular disease, though its utility for predicting long-term mortality appears limited.

Abstract

HALP score shows promise as a biomarker for STM in CVD patients. However, its predictive value for long-term mortality is limited. Further research is needed to confirm its diagnostic accuracy and clinical utility for both mortality outcomes.

Bookmark

Cite This Study

Lu et al. (Fri,) studied this question.

synapsesocial.com/papers/69dc88583afacbeac03ea386 https://doi.org/https://doi.org/10.1177/10815589261444736

Bookmark